In a recent Reuters Events poll, 43% of pharma said that reimbursement policy and legislation (e.g Best Price) is the most significant challenge in addressing market access issues related to cell and gene therapies. While there are indeed many common goals amongst pharma and healthcare when it comes to improving patient outcomes – and looking for a cure – affordability is still the number one obstacle.
In this panel (filmed at the start of November), with 4 cell & gene therapy market access experts, we look at how to:
- Assess the economic stress on payers caused by the pandemic and the knock-on effect this could have on access to therapies
- Co-create a new paradigm for financing treatments, involving government, non-profit, payers, pharma and/or other New routes to reimbursement?
- Explore novel pricing solutions, contracts and alternative models including subscriptions, pay for performance and instalments
Watch this session and hear from:
- Mark Trusheim, Strategic Director (and Biotech Exec including Precision Financing for Gene Therapies), MIT NEWDIGS with the latest data from FoCUS on data from US payers – on their concerns and what kind of financing they prefer
- Lung-I Cheng, Director Value and Access Oncology, Takeda on the impact that COVID-19 has had, and will have on market access
As well as Nick Li, Senior Director, Health Economics and Outcomes Research (HEOR), UniQure and Don Creighton, Managing Director, Huron Consulting Group.
